CDER’s latest proposal to withdraw the accelerated approval of Makena (HPC) was dependent on a substantial randomized trial that failed to confirm the benefit of this drug to newborns or reduce the risk of PTB. In https://dawudzauu903257.wikicorrespondence.com/user